Multiple System Atrophy

Global Multiple System Atrophy Market to Reach US$163.5 Million by 2030

The global market for Multiple System Atrophy estimated at US$145.2 Million in the year 2024, is expected to reach US$163.5 Million by 2030, growing at a CAGR of 2.0% over the analysis period 2024-2030. Magnetic Resonance Imaging, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$67.3 Million by the end of the analysis period. Growth in the Positron Emission Tomography segment is estimated at 1.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$39.6 Million While China is Forecast to Grow at 4.1% CAGR

The Multiple System Atrophy market in the U.S. is estimated at US$39.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$31.0 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Multiple System Atrophy Market - Key Trends & Drivers Summarized

Why Is Multiple System Atrophy a Focus Area in Neurodegenerative Disease Research?

Multiple System Atrophy (MSA) is a rare and progressive neurodegenerative disorder that affects multiple regions of the central nervous system, leading to a combination of movement, autonomic, and cerebellar symptoms. The disease shares features with Parkinson’s disease but progresses more rapidly and lacks sustained response to dopaminergic therapy. Diagnosis is clinically challenging due to symptom overlap with other movement disorders, often resulting in delayed intervention. This complexity has placed MSA under increased clinical and research attention, particularly as early and accurate diagnosis is critical for care planning and trial enrollment.

The condition is categorized into two subtypes: MSA-P (parkinsonian) and MSA-C (cerebellar), depending on the predominant symptom profile. Both forms involve widespread alpha-synuclein accumulation in glial cells, distinguishing MSA pathologically from Parkinson’s and other related disorders. Management is currently symptomatic, focusing on improving quality of life through pharmacological and supportive therapies, as no curative treatment exists. This unmet need continues to drive new approaches in diagnostics, disease-modifying therapies, and multidisciplinary care frameworks.

What Therapeutic Strategies Are Being Explored to Address MSA?

Current treatment strategies remain palliative, aimed at managing motor symptoms with dopaminergic agents and addressing autonomic dysfunction with medications that stabilize blood pressure, bladder function, and sleep disturbances. However, limited and short-lived responses highlight the urgent need for disease-modifying options. Several research programs are now investigating approaches that target alpha-synuclein aggregation, neuroinflammation, and mitochondrial dysfunction, which are believed to underlie disease progression.

Clinical trials are evaluating small molecules, monoclonal antibodies, and gene therapies that intervene in neurodegenerative pathways. Some investigational drugs aim to slow glial cell damage or modulate immune system activity within the brain. Interest is also growing in regenerative strategies, including stem cell-based therapies, though these remain at early research stages. As research continues, patient registries, biomarker identification, and improved imaging tools are playing a key role in refining study designs and enabling earlier intervention.

Which Healthcare Systems and Patient Needs Influence Market Dynamics?

Due to its rarity, MSA is typically managed at specialized neurology centers that offer coordinated care from movement disorder specialists, autonomic experts, and rehabilitative professionals. The condition places a high burden on caregivers and healthcare systems due to its rapid progression and multi-system involvement. Patients often require a combination of pharmacological support, physical therapy, speech therapy, and assistive technologies. Early access to multidisciplinary care and patient education can delay complications and improve day-to-day functioning.

Public awareness remains low, leading to underdiagnosis and inconsistent care pathways across different regions. Advocacy organizations are working to expand education, patient support, and clinical trial participation. Diagnostic uncertainty continues to hinder access to targeted treatments and appropriate referrals. Increasing awareness among primary care physicians and neurologists is essential to improve early detection and reduce misdiagnosis rates, which currently remain high for MSA.

Growth in the Multiple System Atrophy Market Is Driven by Several Factors…

Growth in the multiple system atrophy market is driven by several factors. Rising diagnostic capabilities and neuroimaging tools are improving identification and subtyping of patients. Increased research investment in rare neurodegenerative diseases is leading to more clinical trials targeting underlying disease mechanisms. Expansion of patient advocacy networks supports awareness, education, and trial recruitment. Advances in biomarker research and imaging methods facilitate earlier diagnosis and intervention. Broader access to multidisciplinary care models and symptom management strategies improves long-term patient outcomes. Lastly, regulatory interest in supporting orphan drug development accelerates innovation and investment in this challenging and underserved disease area.       

SCOPE OF STUDY:

The report analyzes the Multiple System Atrophy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Diagnosis Type (Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test, Other Diagnosis Types); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• AC Immune
• Alterity Therapeutics
• Asklepios BioPharmaceutical (AskBio)
• AstraZeneca plc
• Biohaven Pharmaceuticals
• Biogen Idec
• Brain Neurotherapy Bio, Inc.
• Corestem, Inc.
• H. Lundbeck A/S
• Inhibikase Therapeutics
• Ionis Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Modag GmbH
• Neuramedy
• ProMIS Neurosciences Inc.
• Retrotpe
• Sanofi S.A.
• Stealth BioTherapeutics Corp.
• Theravance Biopharma, Inc.
• Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.